vs
Dianthus Therapeutics, Inc.（DNTH）与SELLAS Life Sciences Group, Inc.（SLS）财务数据对比。点击上方公司名可切换其他公司
Dianthus Therapeutics, Inc.的季度营收约是SELLAS Life Sciences Group, Inc.的3.6倍（$284.0K vs $79.0K），SELLAS Life Sciences Group, Inc.净利率更高（-12108.9% vs -22687.3%，领先10578.5%）
Dianthus Therapeutics是一家临床阶段生物制药企业，专注开发罕见免疫与炎症疾病的新型靶向疗法，其抗体类候选管线聚焦解决重症患者未满足医疗需求，主要在北美开展临床研究与合作。
SELLAS生命科学集团是一家处于后期临床阶段的生物制药企业，专注于开发针对未满足医疗需求的创新癌症免疫疗法，管线覆盖血液恶性肿瘤与实体瘤，核心候选产品适配急性髓系白血病等适应症，主要市场布局北美区域。
DNTH vs SLS — 直观对比
营收规模更大
DNTH
是对方的3.6倍
$79.0K
净利率更高
SLS
高出10578.5%
-22687.3%
损益表 — Q4 FY2025 vs Q1 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $284.0K | $79.0K |
| 净利润 | $-64.4M | $-9.6M |
| 毛利率 | — | — |
| 营业利润率 | -24486.3% | -12208.9% |
| 净利率 | -22687.3% | -12108.9% |
| 营收同比 | -78.6% | — |
| 净利润同比 | -126.6% | 13.8% |
| 每股收益（稀释后） | $-1.53 | $-0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNTHSLS
| Q4 25 | $284.0K | — | ||
| Q3 25 | $396.0K | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $874.0K | $79.0K | ||
| Q3 23 | $924.0K | — |
净利润DNTHSLS
| Q4 25 | $-64.4M | — | ||
| Q3 25 | $-36.8M | — | ||
| Q1 25 | $-29.5M | — | ||
| Q4 24 | $-28.4M | — | ||
| Q3 24 | $-25.2M | — | ||
| Q2 24 | $-17.6M | — | ||
| Q1 24 | $-13.7M | $-9.6M | ||
| Q3 23 | $-14.8M | — |
营业利润率DNTHSLS
| Q4 25 | -24486.3% | — | ||
| Q3 25 | -10173.7% | — | ||
| Q1 25 | -2852.7% | — | ||
| Q4 24 | -2406.9% | — | ||
| Q3 24 | -1376.6% | — | ||
| Q2 24 | -1191.8% | — | ||
| Q1 24 | -2041.6% | -12208.9% | ||
| Q3 23 | -1705.5% | — |
净利率DNTHSLS
| Q4 25 | -22687.3% | — | ||
| Q3 25 | -9284.1% | — | ||
| Q1 25 | -2537.5% | — | ||
| Q4 24 | -2144.8% | — | ||
| Q3 24 | -1159.0% | — | ||
| Q2 24 | -945.1% | — | ||
| Q1 24 | -1573.0% | -12108.9% | ||
| Q3 23 | -1597.7% | — |
每股收益（稀释后）DNTHSLS
| Q4 25 | $-1.53 | — | ||
| Q3 25 | $-0.97 | — | ||
| Q1 25 | $-0.82 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.74 | — | ||
| Q2 24 | $-0.51 | — | ||
| Q1 24 | $-0.54 | $-0.21 | ||
| Q3 23 | $-3.78 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $404.3M | $18.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $493.4M | $9.7M |
| 总资产 | $530.9M | $24.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNTHSLS
| Q4 25 | $404.3M | — | ||
| Q3 25 | $402.6M | — | ||
| Q1 25 | $263.2M | — | ||
| Q4 24 | $275.2M | — | ||
| Q3 24 | $281.1M | — | ||
| Q2 24 | $360.7M | — | ||
| Q1 24 | $377.0M | $18.4M | ||
| Q3 23 | $189.9M | — |
股东权益DNTHSLS
| Q4 25 | $493.4M | — | ||
| Q3 25 | $546.5M | — | ||
| Q1 25 | $328.6M | — | ||
| Q4 24 | $352.5M | — | ||
| Q3 24 | $337.9M | — | ||
| Q2 24 | $358.2M | — | ||
| Q1 24 | $372.7M | $9.7M | ||
| Q3 23 | $178.4M | — |
总资产DNTHSLS
| Q4 25 | $530.9M | — | ||
| Q3 25 | $577.4M | — | ||
| Q1 25 | $348.6M | — | ||
| Q4 24 | $374.0M | — | ||
| Q3 24 | $354.2M | — | ||
| Q2 24 | $369.0M | — | ||
| Q1 24 | $382.5M | $24.4M | ||
| Q3 23 | $192.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.0M | $-10.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.1M | — |
| 自由现金流率自由现金流/营收 | -16591.9% | — |
| 资本支出强度资本支出/营收 | 48.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-132.8M | — |
8季度趋势，按日历期对齐
经营现金流DNTHSLS
| Q4 25 | $-47.0M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q1 25 | $-27.6M | — | ||
| Q4 24 | $-27.4M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-14.9M | $-10.8M | ||
| Q3 23 | $-10.0M | — |
自由现金流DNTHSLS
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-27.5M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-15.0M | — | ||
| Q3 23 | $-10.1M | — |
自由现金流率DNTHSLS
| Q4 25 | -16591.9% | — | ||
| Q3 25 | -7717.2% | — | ||
| Q1 25 | -2377.8% | — | ||
| Q4 24 | -2072.0% | — | ||
| Q3 24 | -980.3% | — | ||
| Q2 24 | -780.7% | — | ||
| Q1 24 | -1713.2% | — | ||
| Q3 23 | -1088.4% | — |
资本支出强度DNTHSLS
| Q4 25 | 48.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 3.7% | — | ||
| Q3 23 | 7.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
